Boule Diagnostics AB (publ) (STO:BOUL)

Market Cap	136.69M -57.2%
Revenue (ttm)	478.39M -8.6%
Net Income	-8.05M
EPS	-0.21
Shares Out	38.83M
PE Ratio	n/a
Forward PE	152.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,745
Average Volume	57,289
Open	3.400
Previous Close	3.380
Day's Range	3.400 - 3.610
52-Week Range	3.140 - 10.600
Beta	0.17
RSI	43.18
Earnings Date	Jul 17, 2026

About Boule Diagnostics AB

Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and vet...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1956
• Employees: 200
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BOUL

Financial Performance

In 2025, Boule Diagnostics AB's revenue was 489.69 million, a decrease of -12.31% compared to the previous year's 558.46 million. Losses were -3.75 million, -98.73% less than in 2024.